STOCK TITAN

Nutriband Inc - NTRB STOCK NEWS

Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.

Overview

Nutriband Inc is a Florida-based pharmaceutical company specializing in the development of transdermal drug delivery systems that incorporate advanced abuse-deterrent technologies. Its core business revolves around transdermal pharmaceutical products engineered to mitigate the risks of drug abuse, misuse, diversion, and accidental exposure, with a special emphasis on addressing the global opioid crisis. Utilizing proprietary technology that integrates aversive agents into transdermal patches, Nutriband is dedicated to improving patient safety while ensuring essential medications remain accessible for those in need.

Advanced Abuse-Deterrent Technology

The company’s flagship innovation, AVERSA technology, is designed to deter the oral abuse of potent drugs by utilizing taste aversion methods. This technology can be incorporated into various transdermal patches, a critical step toward preventing accidental exposures—particularly in vulnerable populations such as young children. The patented approach provides an additional safeguard by making the potential for abuse less appealing, thereby enhancing the overall safety profile of drugs with abuse potential.

Business Model and Operations

Nutriband Inc generates revenue primarily through the sale of consumer transdermal and coated products, as well as through contract manufacturing services provided by its wholly owned subsidiary, Pocono Pharma. The company leverages its strategic partnerships with top industry players to extend its market reach, including engagements with major retailers and established pharmaceutical manufacturing organizations. This diversified revenue approach not only supports the current portfolio but also positions Nutriband as a flexible partner in both the healthcare and contract manufacturing sectors.

Strategic Partnerships and Intellectual Property

A cornerstone of Nutriband’s success is its robust global intellectual property portfolio, which spans across more than 40 countries including the United States, Europe, Japan, and Australia. Such extensive protection underpins its innovative AVERSA technology and provides a competitive edge in the increasingly critical field of abuse-deterrent transdermal systems. Strategic alliances with industry experts such as Kindeva Drug Delivery further reinforce its position by ensuring that large-scale manufacturing processes align with FDA guidelines and international industry standards.

Market Position and Industry Significance

Operating at the nexus of pharmaceutical innovation and patient safety, Nutriband Inc is positioned distinctively in the competitive landscape of transdermal drug delivery systems. Its strategic focus on developing abuse-deterrent products addresses a significant unmet need in the market, particularly in the context of managing opioid-related risks without compromising therapeutic access. Through its commitment to evolving industry standards and enhancing product safety, Nutriband has established itself as a forward-thinking entity within a critical market segment.

Product Portfolio and Future Applications

While its lead product, an abuse-deterrent fentanyl patch, remains at the forefront of its development efforts, Nutriband is actively expanding its portfolio to include additional transdermal therapies. By integrating its core AVERSA technology across multiple product lines, the company aims to address a wide spectrum of medications with abuse potential, including opioids and stimulants. This strategy not only diversifies its technology applications but also solidifies its reputation as an innovator in transdermal pharmaceutical solutions.

Commitment to Safety and Regulatory Compliance

At the heart of Nutriband’s mission is a dedication to enhancing patient safety through rigorous research, development, and close adherence to regulatory standards. The company emphasizes clear, methodical approaches that streamline market entry while upholding the highest safety measures. This balance of innovation and compliance is critical in a market where the prevention of misuse and accidental exposure is of paramount concern.

Overall, Nutriband Inc exemplifies a strategic blend of innovative product development, methodical market expansion, and a steadfast commitment to patient safety. Its robust technology platform, significant IP portfolio, and established industry partnerships underscore its role as a key contributor to the evolution of abuse-deterrent pharmaceutical products.

Rhea-AI Summary

Nutriband (NASDAQ:NTRB), a developer of transdermal pharmaceuticals and technology, will host an exclusive live investor webinar on May 30, 2024, at 4:15 p.m. ET.

Organized by RedChip Companies, the event will feature Chairman Serguei Melnik and CEO Gareth Sheridan, who will provide insights into the company's current operations and future milestones.

Investors can register for the free webinar and submit questions beforehand or during the live session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
-
Rhea-AI Summary

Nutriband announced the appointment of Sergei Glinka to its board of directors. Glinka, an experienced business leader, brings a wealth of experience from his roles in major European companies. The Glinka family has invested $4.5 million in Nutriband via a private placement in April 2024, which totaled $8.4 million. Nutriband aims to use these funds to complete the FDA approval process for its AVERSA™ technology. AVERSA™, currently patented in 45 countries, is projected to reach peak annual US sales between $80 million and $200 million. The global opioid market was valued at $22.8 billion in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
management
-
Rhea-AI Summary

RedChip Companies will air interviews with Can-Fite BioPharma (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, discusses the company's advanced clinical stage drug development focusing on oncology and inflammatory diseases. Can-Fite has two drug candidates in advanced stages of development with registration plans agreed with the U.S. FDA and the EMA. Gareth Sheridan, Founder and CEO of Nutriband, talks about their AVERSA™ abuse-deterrent transdermal technology to address the global opioid crisis. Nutriband's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Nutriband Inc. announced the closing of an $8.4 million private placement to fund the commercial development of AVERSA Fentanyl, an abuse-deterrent opioid patch. The company aims to reach peak annual US sales of $80 million to $200 million. Nutriband is working with Kindeva Drug Delivery to develop the commercial manufacturing process for the product. The development milestones include FDA IND filing, pivotal human abuse potential clinical study, and NDA filing. The company targets Q1 of 2025 for NDA submission. Nutriband's AVERSA technology shows promising abuse-deterrent properties in preliminary studies. The company plans to file a 505(b)(2) NDA based on a single Phase 1 human abuse potential clinical study, potentially receiving expedited FDA review. Nutriband's pipeline includes abuse deterrent versions of fentanyl, buprenorphine, and methylphenidate transdermal patches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.15%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. has signed an exclusive supplier agreement with Fit For Life Group, a major brand license holder, for the launch of a new product under one of their top brands. The agreement was fully executed on April 19, 2024. Nutriband's subsidiary, Active Intelligence, will serve as the manufacturer. Fit For Life Group, founded in 2016, is a prominent player in the fitness equipment and yoga accessories market, with a strong brand portfolio including Gaiam, Reebok, Adidas, New Balance, SPRI, and FILA. They target a wide range of consumers from beginners to professionals, with distribution through major retailers like Target, Walmart, Dick's Sporting Goods, and Amazon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. has announced an $8.4M private placement to fund the development of AVERSA™ Fentanyl and target FDA approval in Q1 2025. The company has entered into securities purchase agreements for the sale of 2,100,000 shares of common stock at $4 per share, with investors receiving warrants to purchase additional shares at $6.43 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
Rhea-AI Summary
Nutriband Inc. announces engagement with Fit For Life Group, a major brand license holder, for manufacturing innovative products. Fit For Life Group, a market leader in fitness equipment and yoga accessories, has partnered with Nutriband to create innovative products for a wide range of consumers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.96%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. announces the development of AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal patch, through a 505(b)(2) New Drug Application (NDA) pathway. Partnering with Kindeva Drug Delivery, Nutriband aims to revolutionize the opioid market by incorporating their AVERSA™ technology into FDA-approved transdermal fentanyl patches. The NDA submission will be based on a single Phase 1 human abuse potential clinical study, eliminating the need for Phase 2 or 3 trials. This streamlined regulatory process could lead to expedited FDA review, potentially making AVERSA™ Fentanyl the first abuse-deterrent patch approved globally. Market analysis projects peak annual US sales of $80 million to $200 million for AVERSA™ Fentanyl, tapping into the $22.8 billion global opioid market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.22%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. presents data on transdermal patch abuse and accidental pediatric exposure at the 2024 AAPM Annual Meeting. The company's AVERSA™ technology aims to provide safer abuse-deterrent transdermal patches for opioid and stimulant drugs, addressing a critical unmet need in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
Rhea-AI Summary
Nutriband Inc. announces data on transdermal patch abuse and accidental exposure to be presented at the 2024 AAPM Annual Meeting. The company collaborated with RMPDS to determine abuse rates in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
none

FAQ

What is the current stock price of Nutriband (NTRB)?

The current stock price of Nutriband (NTRB) is $5.5 as of April 3, 2025.

What is the market cap of Nutriband (NTRB)?

The market cap of Nutriband (NTRB) is approximately 63.6M.

What is Nutriband Inc's core business?

Nutriband Inc focuses on the development of transdermal pharmaceutical products using innovative abuse-deterrent technology. The company is dedicated to enhancing patient safety by preventing the misuse and accidental exposure of drugs with abuse potential.

How does the AVERSA technology work?

AVERSA technology incorporates aversive agents into transdermal patches to deter drug abuse by triggering an immediate taste aversion. This approach reduces the likelihood of misuse, diversion, or accidental ingestion of potent medications.

What are the key revenue streams for Nutriband Inc?

The company generates revenue primarily through the sale of consumer transdermal and coated products, as well as through its contract manufacturing services via its subsidiary, Pocono Pharma. These diversified streams support both product development and manufacturing partnerships.

How does Nutriband position itself within the pharmaceutical industry?

Nutriband occupies a strategic niche in the pharmaceutical sector by targeting the critical issue of drug abuse. Its advanced abuse-deterrent technology and robust intellectual property portfolio distinguish its products, particularly in addressing opioid-related safety concerns.

What strategic partnerships support Nutriband's operations?

Nutriband collaborates with respected industry partners like Kindeva Drug Delivery and Pocono Pharma. These partnerships enhance its manufacturing capabilities and ensure compliance with regulatory standards, broadening its market reach.

In which markets are Nutriband's products available?

While Nutriband is based in the United States, its operations and intellectual property extend globally, covering key markets in Europe, Japan, Australia, and more. The company’s strategic licensing and distribution agreements support international market penetration.

How is Nutriband addressing the opioid crisis?

Nutriband is developing abuse-deterrent transdermal solutions specifically designed to mitigate opioid misuse. By incorporating aversive agents into its patches, the company aims to prevent both intentional abuse and accidental exposure.

How does Nutriband protect its innovative technology?

The company maintains a comprehensive global intellectual property portfolio with patents issued in over 40 countries. This extensive protection secures its AVERSA technology and reinforces its competitive advantage in the transdermal pharmaceutical space.
Nutriband Inc

Nasdaq:NTRB

NTRB Rankings

NTRB Stock Data

63.58M
3.30M
70.29%
2.1%
2.53%
Biotechnology
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
ORLANDO